Second-Generation Nitazoxanide Derivatives: Thiazolides are Effective Inhibitors of the Influenza a Virus | Zendy

Andrew V. Stachulski | Zendy; M. Gabriella Santoro | Zendy; Sara Piacentini | Zendy; Giuseppe Belardo | Zendy; Simone La Frazia | Zendy; Chandrakala Pidathala | Zendy; Eleanor C. Row | Zendy; Neil G. Berry | Zendy; Mazhar Iqbal | Zendy; Sarah Allman | Zendy; J. Edward Semple | Zendy; Brian M Eklov | Zendy; Paul M. O’Neill | Zendy; JeanFrançois Rossignol | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Second-Generation Nitazoxanide Derivatives: Thiazolides are Effective Inhibitors of the Influenza a Virus

Author(s) -

Andrew V. Stachulski,

M. Gabriella Santoro,

Sara Piacentini,

Giuseppe Belardo,

Simone La Frazia,

Chandrakala Pidathala,

Eleanor C. Row,

Neil G. Berry,

Mazhar Iqbal,

Sarah Allman,

J. Edward Semple,

Brian M Eklov,

Paul M. O’Neill,

JeanFrançois Rossignol

Publication year - 2018

Publication title -

future medicinal chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.708

H-Index - 69

eISSN - 1756-8927

pISSN - 1756-8919

DOI - 10.4155/fmc-2017-0217

Subject(s) - nitazoxanide , influenza a virus , virus , druggability , strain (injury) , virology , pharmacology , chemistry , medicine , biology , immunology , biochemistry , gene

The only small molecule drugs currently available for treatment of influenza A virus (IAV) are M2 ion channel blockers and sialidase inhibitors. The prototype thiazolide, nitazoxanide, has successfully completed Phase III clinical trials against acute uncomplicated influenza.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research